U 101958

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H462806

CAS#: 170856-57-2

Description: U 101958 is a putative antipsychotic agent It is also a highly selective dopamine D4 receptor antagonist.


Chemical Structure

img
U 101958
CAS# 170856-57-2

Theoretical Analysis

Hodoodo Cat#: H462806
Name: U 101958
CAS#: 170856-57-2
Chemical Formula: C21H29N3O
Exact Mass: 339.23
Molecular Weight: 339.483
Elemental Analysis: C, 74.30; H, 8.61; N, 12.38; O, 4.71

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: U-101958;

IUPAC/Chemical Name: N-(1-benzylpiperidin-4-yl)-3-isopropoxy-N-methylpyridin-2-amine

InChi Key: WFLHEXUTTRRXFJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H29N3O/c1-17(2)25-20-10-7-13-22-21(20)23(3)19-11-14-24(15-12-19)16-18-8-5-4-6-9-18/h4-10,13,17,19H,11-12,14-16H2,1-3H3

SMILES Code: CC(Oc1c(N(C2CCN(CC2)Cc3ccccc3)C)nccc1)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 339.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M, Schoeffter P. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. Br J Pharmacol. 1998 Jul;124(5):889-96. doi: 10.1038/sj.bjp.0701921. PMID: 9692773; PMCID: PMC1565470.

2: Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Langenegger D, Sommer B, Hoyer D, Tricklebank M, Schoeffter P. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br J Pharmacol. 1999 Oct;128(3):613-20. doi: 10.1038/sj.bjp.0702849. PMID: 10516640; PMCID: PMC1571689.

3: Helmeste DM, Shioiri T, Mitsuhashi M, Tang SW. Binding of [3H]U-101958 to sigma1 receptor-like sites in human cerebellum and neuroblastoma cells. Eur J Pharmacol. 1999 Apr 9;370(2):205-9. doi: 10.1016/s0014-2999(99)00137-5. PMID: 10323271.

4: Florán B, Florán L, Erlij D, Aceves J. Activation of dopamine D4 receptors modulates [3H]GABA release in slices of the rat thalamic reticular nucleus. Neuropharmacology. 2004 Mar;46(4):497-503. doi: 10.1016/j.neuropharm.2003.10.004. PMID: 14975673.

5: Schlachter SK, Poel TJ, Lawson CF, Dinh DM, Lajiness ME, Romero AG, Rees SA, Duncan JN, Smith MW. Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 1997 Mar 19;322(2-3):283-6. doi: 10.1016/s0014-2999(97)00013-7. PMID: 9098699.

6: De La Garza R 2nd, Madras BK. [(3)H]PNU-101958, a D(4) dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. Synapse. 2000 Sep 1;37(3):232-44. doi: 10.1002/1098-2396(20000901)37:3<232::AID-SYN7>3.0.CO;2-7. PMID: 10881045.

7: Gazi L, Schoeffter P, Nunn C, Croskery K, Hoyer D, Feuerbach D. Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):555-64. doi: 10.1007/s002100000236. PMID: 10832611.

8: Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12;367(1):139-42. doi: 10.1016/s0014-2999(98)00980-7. PMID: 10082277.

9: Kula NS, Baldessarini RJ, Kebabian JW, Bakthavachalam V, Xu L. RBI-257: a highly potent dopamine D4 receptor-selective ligand. Eur J Pharmacol. 1997 Jul 23;331(2-3):333-6. doi: 10.1016/s0014-2999(97)01065-0. PMID: 9274997.

10: Wilke RA, Hsu SF, Jackson MB. Dopamine D4 receptor mediated inhibition of potassium current in neurohypophysial nerve terminals. J Pharmacol Exp Ther. 1998 Feb;284(2):542-8. PMID: 9454795.

11: Sharma A, Kramer ML, Wick PF, Liu D, Chari S, Shim S, Tan W, Ouellette D, Nagata M, DuRand CJ, Kotb M, Deth RC. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol Psychiatry. 1999 May;4(3):235-46. doi: 10.1038/sj.mp.4000522. PMID: 10395213.